Phase 2 N=23 Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Bacterial Enteritis
Primary: Bacterial Elimination Rate (BER) in the CDI and EI Groups — 100.0; 72.7; 90.0; 87.5 percentage of participants
Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
Phase 2 N=10 A Study of INCB050465 in Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Proportion of Participants With a 1 Point or Greater Change on the Salivary Gland Ultrasound (SGUS) Score for Parotid and Submandibular Glands — 0; 0 Participants
Phase 2 N=301 Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
Septic Shock
Primary: Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality) — 63.1453; 63.1578; 64.5744; 63.9809 days
Phase 2 N=11 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Melanoma · Meningioma · Breast Cancer
Primary: Percentage of Participants With a Response — 10; 50 percentage of participants
Phase 2 N=2 Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
Dravet Syndrome
Primary: Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit — 39; 14 General tonic-clonic seizures
Phase 2 N=597 Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health
Vitamin d Deficiency
Primary: Serum 25-hydroxyvitamin D Concentrations in Schoolchildren — 8; 8; 10; 7 ng/ml
Phase 2 N=44 Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Alzheimer's Disease
Primary: Adverse Events (AEs) by Body System — 5; 2; 6; 5 Adverse Events
Phase 2 N=120 International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Number of Patients With PASI 75 Response After 12 Weeks of Therapy — 24; 25; 26; 6 Participants
Phase 2 N=7 TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Metastatic Ovarian Cancer
Primary: Number of Participants With Reported Adverse Events by Type — 3; 3; 1; 1 Participants
Phase 2 N=30 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia-2 · High Grade Malignant Neoplasm
Primary: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant — 9; 21 Participants
Phase 2 N=12 Ketamine and Prolonged Exposure in PTSD
Post-traumatic Stress Disorder
Primary: Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms — 15.3 units on a scale
Phase 2 N=10 Aurinia Early Urinary Protein Reduction Predicts Response
Lupus Nephritis
Primary: Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR) — 7 Participants
Phase 2 N=29 Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Head and Neck Cancer
Primary: 20 Week Progression Free Survival Rate — 0.90 proportion of participants